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HIV/AIDS is not a neglected disease.
Histoplasmosis is not considered a neglec-
ted disease in North America. However, in
South America, it should be. It often
affects neglected populations and repre-
sents a lethal blind spot of the HIV/AIDS
data collection systems. Counts of new
AIDS cases and AIDS-related deaths are
useful to follow the epidemic; however,
they overlook the exact cause of death. In
the context of the South American path-
ogen ecology, the systemic mycosis due to
Histoplasma capsulatum var. capsulatum is
probably on the top of the list of AIDS-
defining illnesses and AIDS-related deaths
[1], yet it is mostly undiagnosed and is not
even on the diagnostic algorithm used by a
significant proportion of clinicians facing a
febrile, severely immunodepressed patient
in the region.
The Invisible Burden
Studies performed in the 1950s and
1960s on the histoplasmin skin test posi-
tivity in South America showed positivity
rates around 30% from Trinidad and Tobago
in the North, to Uruguay and Argentina in
the South. The pathogen is there [2].
Despite this, expertise and awareness of
this disease is limited to mycologists and
some clinical teams scattered throughout
the South American continent [2–16]. But
those with expertise are the exception
rather than the rule. Imported cases in
Europe occurring in HIV-infected residents
or travellers from South America, notably
in France, Spain, and Italy, are starting to be
recognized, but often late in the course of the
disease because clinicians are not familiar
with this ‘‘endemic’’ disease [17–19].
For too long, the absence of a simple,
reliable, and affordable diagnostic test has
made it difficult to determine the burden
of this disease in HIV-infected patients in
much of South America. The gold stan-
dard for diagnosis relies, so far, on the
culture of fluid and tissue samples [20].
This requires invasive investigations by
clinicians (bone marrow aspirates; biopsies
of the liver, lymph node, and intestine;
etc.). From the lab perspective, direct
examination may accelerate diagnosis,
but culture may take weeks and require a
BSL 2 laboratory. Detection of specific
antigens in serum or urine samples is not
available for diagnosis in most of South
America, and galactomannan detection
(cross reactivity during histoplasmosis) is
not being used as a standard of care.
Contact with clinicians from various
countries suggests that, although severe
histoplasmosis often kills in a few days,
most clinicians are not very aggressive in
their investigations. Moreover, presump-
tive antifungal therapy is rare. Biopsies are
usually immersed in formalin by surgeons
rather than sent for culture. Most often,
clinicians do not take proper samples for
mycological diagnosis, creating a vicious
cycle that diminishes the capacity of myco-
logical laboratories and perpetuates under-
funding and the absence of diagnosis and,
thus, the ‘‘nonexistence’’ of the very disease
that is killing numerous patients.
In French Guiana, there has been a
mycology laboratory since 1997 with a
BSL 3 laboratory. The virtuous cycle
between laboratory and clinicians has
been fruitful: clinicians are well informed
about histoplasmosis and are quite aggres-
sive in looking for the infection, while the
mycology laboratory has the capacity to
appropriately process and identify Histo-
plasma in clinical specimens [21]. Although
published maps [2] show no histoplasmo-
sis in most of French Guiana, the recent
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figures that have emerged are striking.
With 1.5 cases per 100 patient-years,
histoplasmosis is the most common cause
of AIDS-defining illness. Interestingly, des-
pite awareness of this disease and avail-
ability of liposomal amphotericin B, it has
also been the leading cause of AIDS-
related death for decades. A recent 2-year
study of all HIV patients admitted in Saint
Laurent du Maroni hospital showed that
41% of admitted patients with CD4 counts
below 200 had disseminated histoplasmo-
sis, and 85% of admitted patients with
CD4 counts below 50 and isolated fever
had disseminated histoplasmosis. This is a
clear message for physicians when admitting
a severely immunodepressed HIV patient in
the region: ‘‘Don’t miss histoplasmosis!’’
No Data = No Existence.
Meanwhile, Patients Continue
Dying from a Treatable
Disease…
The high prevalence of HIV–Histoplas-
ma coinfections on the South American
continent is not a trivial problem. The
scarcity of the published research on this
topic reflects the tragic fact that this
problem is evolving under the radar of
health care systems and is truly a neglected
disease. Generations of young doctors will
learn to look for tuberculosis, pneumocys-
tosis, and bacterial pneumonia when
confronted with a febrile patient with
respiratory signs, but not for histoplasmo-
sis. Similarly, important clinical clues, such
as cytopenia (ascribed to bone marrow
involvement with or without haemopha-
gocytic syndrome) and liver enzyme ab-
normalities will often not lead to the
suspicion of disseminated histoplasmosis.
A big danger is that a smear negative,
treatment resistant, ‘‘tuberculosis-like’’ syn-
drome may often be labelled drug-resistant
tuberculosis, when it was never tuberculosis
in the first place. It is thus of paramount
importance to fill this knowledge gap and
revise the diagnostic and therapeutic algo-
rithms in the region. The ‘‘Know your
epidemic, know your response’’ UNAIDS slogan
should also be applied to histoplasmosis.
We Need Research and We
Need to Act Now
The HIV/AIDS epidemic is still active
in countries in the Amazon basin. Guyana,
Suriname, French Guiana, and the Bra-
zilian state of Amapa all have HIV
prevalence rates over 1% of the popula-
tion. Although the AIDS incidence has
steadily declined in the southern states of
Brazil, the situation in the northern
(Amazonas, Roraima, and Amapa) and
the northeastern states of Brazil is still
concerning. A very coarse calculation
based on 600,000 HIV patients and an
annual histoplasmosis incidence rate of
1.5% would estimate the annual number
of cases to be in the thousands. Unfortu-
nately, histoplasmosis thus still has a future
in HIV patients. Although there is a need
for epidemiologic research to measure the
true burden of disease in various regions of
South America, actions can, and should,
be taken to diagnose and treat patients
now. We need to develop standard myco-
logical practices in the area that emphasize
early and aggressive clinical diagnosis, and
we need to develop new rapid diagnostic
tools and advocate for affordable treat-
ment. New affordable diagnostic assays
(CDC, Immy) are presently being tested in
Brazil, French Guiana, Suriname, and
Colombia. We hope they will allow us to
improve our knowledge of local epidemi-
ologies and reduce patient mortality
through early diagnosis and increased
awareness. Although amphotericin B is
available, it has potential significant renal
side effects. Liposomal amphotericin B is
the treatment of choice of the most severe
cases of HIV-associated histoplasmosis,
but its cost exceeds 800 US dollars per
day. Gilead Sciences, Inc. has committed
to the procurement of HIV drugs at
affordable prices. Extending this policy to
the problem of treating HIV-associated
histoplasmosis, a neglected disease, would
be an important step in improving the
health of HIV/AIDS patients in the
region. In the near future, DNDi (Drugs
for Neglected Diseases initiative) should
provide a low-cost, heat-stable alternative
to liposomal amphotericin B that could be
valuable for histoplasmosis treatment. Our
focus has been HIV-associated dissemi-
nated histoplasmosis; however, it should
be emphasized that the problem of missing
the diagnosis of histoplasmosis in South
America also extends to some immuno-
competent patients or patients with causes
of immunodepression other than HIV
[22].
We need tests; we need treatments; but
first of all, we physicians need to integrate
our South American epidemiology in our
diagnostic algorithms. Looking for malaria
in febrile patients in malaria-endemic
areas is automatic; looking for histoplas-
mosis in febrile, immunosuppressed, HIV-
infected patients in South America, Cen-
tral America, and perhaps way beyond
[23,24], is not. The sooner we do it, the
better for our patients.
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